Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

       124 upvotes 2 years ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community 3 Months update - cannot believe it

       1557 upvotes 1 year ago
      A user shared their positive experience with hair regrowth after three months using topical minoxidil twice daily, 1mg finasteride every morning, and microneedling every 10 days. They reported no side effects and encouraged others to consider similar treatments.

      community Verteporfin and Microneedling

      in Treatments 2 years ago
      Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

    Learn

    3 / 800 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn Dutasteride

      • Dutasteride side effects: what the label and studies actually report The Avodart label reports impotence in 4.7% and decreased libido in 3.0% of men in the first six months (1.7% and 1.4% on placebo), with new reports falling after month six; those figures come from BPH trials in older men, and the hair-loss trials in younger men run only six months. The label and studies also flag a PSA drop of about half, a small rise in high-grade prostate cancer in one trial, an observational link to depression, and sexual effects that the label says may persist after stopping.